antiplatelet
美 [æn't?ple?tlet] 
英 [æn't?ple?tlet]
- adj.抗血小板的
- 網絡抗血小板藥物；冠心癥治療的常用藥物
英漢解釋
例句
The FDA also recommends prolonged dual antiplatelet therapy for at least a year following the intervention.
FDA也推薦介入治療后至少延長一年對病人進行雙重抗血小板治療。
The nanoparticles "hold immense potential to be promoted as an antiplatelet agent, " the researchers note.
研究者們指出“納米粒子是一種極具潛力的抗血小板聚集制劑”。
Antiplatelet therapy is one of the important measures in the secondary prevention of ischemic stroke.
抗血小板治療是缺血性卒中二級預防的重要措施之一。
They did not find nearly as strong a link between antiplatelet agents and ICH as that between anticoagulation and hemorrhages , she added.
她補充說，他們發現抗血小板藥物與顱內出血發病之間的聯系并不如抗凝劑與出血事件之間的聯系那么緊密。
The authors recommended that intensified antiplatelet therapy might be indicated for type 2 diabetic patients.
作者建議強化抗血小板療法可能會用于2型糖尿病患者。
Current therapies for arterial ischemic stroke include thrombolytic, antithrombotic and antiplatelet agents, blood transfusion and surgery.
目前治療手段主要包括溶栓、抗凝、抗血小板、輸血以及外科治療。
The researchers found the risks of developing preeclampsia dropped 10 percent among women taking aspirin or other antiplatelet medications.
研究者發現，相比于服用阿司匹林或者其它抗血小板藥物，患先兆子癇的概率下降了10%。
The search for a useful clinical laboratory diagnostic assay for the antiplatelet antibodies has been long and difficult.
探索有效的檢測血小板抗體的臨床實驗方法經歷了漫長和艱辛的過程。
Aspirin is an effective antiplatelet drug with proven benefit in the primary and secondary prevention of coronary heart disease.
研究背景：阿司匹林是冠心病一級預防和二級預防有效抗血小板藥物。
The report makes a number of practical recommendations to eliminate early discontinuation of antiplatelet therapy.
這個報道列出了多條實用的建議來減少早期停用抗血小板治療。
Antiplatelet Therapy for Secondary Prevention of Cardiovascular Events : More " Advanced " Drug, More Perfect ?
心血管事件的二級預防：抗血小板治療藥物越“先進”越完美嗎？。
What are the factors that may guide the decision to select a specific antiplatelet agent to initiate first after ischemic stroke?
那么，在缺血性卒中后選擇某一種特定藥物開始抗血小板治療時，需要考慮哪些因素？
Antiplatelet drugs, such as Plavix, are used to help prevent potentially dangerous blood clots from forming in people with heart disease.
抗血小板藥物（例如波利維）被用來幫助預防伴心臟病人群中潛在有危險性的血栓形成。
Title: Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation?
抗血小板預防可否減少肝移植術后肝動脈栓塞的發生率？。
New drugs and new technologies, especially antiplatelet and regulation of lipid metabolism are emerging and applying in clinical practice.
新藥物和新技術不斷出現，新藥物和新技術不斷出現，并應用于臨床，尤其是抗血小板應用于臨床，和調節脂質代謝方面
Clinical trial of antithrombotic therapy became the high points, some hopeful new antiplatelet drugs and anticoagulants made their debuts.
其中最令人關注的幾項臨床試驗均涉及抗栓治療，有希望的抗血小板和抗凝新藥紛紛登臺亮相。
These findings underscore the need of individualized antiplatelet treatment regimens in diabetic patients.
這些結果都強調了對于糖尿病患者抗血小板治療方案的個體化需要。
Prolonged antiplatelet therapy with clopidogrel is mandatory after implantation of drug-eluting stents.
長期與氯吡格雷抗血小板治療是強制性植入后藥物涂層支架。
Objective To assess the activity in blood clotting and antiplatelet aggregation of dragon blood from different habitats.
目的考察不同產地血竭在凝血和抗血小板聚集方面的作用。
On-TIME 2 is an important study that gives a number of insights into optimising the antiplatelet regimen in primary PCI.
TIME2是一項重要研究，它在PCI抗血小板治療的優化上提供了更多證據。
International Circulation: Could you please talk about the choice of optimal strategy of early antiplatelet therapy in patients with ACS?
《國際循環》：您能談談ACS患者早期抗血小板治療的最佳策略選擇嗎？
Objective To observe the influence of proton pump inhibitor(PPI) esomeprazole on antiplatelet effect of clopidogrel.
目的觀察質子泵抑制劑埃索美拉唑是否影響氯吡格雷的抗血小板聚集作用。
There is no evidence that antiplatelet agents reduce atherosclerotic risk in patients with HF.
沒有任何證據表明，抗血小板制劑降低心衰患者動脈粥樣硬化的危險。
Cilostazol, the model drug of this study, is a synthetic antiplatelet agent with vasodilating effect.
此研究使用的模式藥物為cilostazol，它是合成的抗凝血制劑并具有血管舒張的作用。
Warfarin is substantially more efficacious (by approximately 40%) than antiplatelet therapy.
而實際上，華法林比抗血小板治療更加有效（大約40%）。
In patients at low risk of GI bleeding, however, the balance of risk and benefit tips away from using PPIs together with antiplatelet drugs.
然而，在處于胃腸道出血低度風險的患者中，風險和獲益的平衡反對同時使用質子泵抑制劑和抗血小板藥物。
Antiplatelet agents are not as effective as warfarin in reducing the risk of thromboembolism in patients with AF.
抗血小板制劑不能象華法林那樣在房顫病中有效地減少血栓栓塞的危險。
Antiplatelet nonspecific antibody and neonatal platelets are more closely related to reduce rates, a statistically significant (P 05).
抗血小板非特異性抗體與新生兒血小板減少發生率關系更為密切，具有統計學意義（P0.05）。
So antiplatelet cure conduce to reduce the harmful events of cardia and cerebrovascular disorder.
抗血小板治療有助于減少心、腦血管不良事件的發生。
We speculate that in the later cohort clinicians were more aware of the risk of DES and prolonged antiplatelet therapy.
我們推測，在后來的隊列研究中，臨床醫師更加重視DES的風險，并延長了抗血小板治療時間。
But these antiplatelet drugs also increase the risk of bleeding, including upper GI bleeding.
但是這些抗血小板藥物也增加出血的風險，包括上消化道出血。
Aspirin is the sole evidence-based antiplatelet drug for treatment of acute ischemic stroke.
阿司匹林是惟一經過循證醫學證明有效并用于急性缺血性卒中的抗血小板藥物。
Conclusions: Currently, eptifibatide is used as the adjunct antiplatelet agent in the majority of patients undergoing primary PCI.
結論——目前，在大多數接受PCI術后的患者中，替非羅班被用來作為抗血小板的輔助治療。
Novel and more potent antiplatelet agents currently under clinical development will be useful in efforts to reach these therapeutic goals.
隨著臨床的發展，當前新型的以及更為有效的抗血小板劑將有助于達到這些治療的效果。
Antiplatelet agents play a major role in thrombus prevention and cure.
抗血小板藥物是最為重要的血栓防治藥物。
In the future, antiplatelet therapy will likely be tailored for the individual patient, they note.
抗血小板治療將來可能只會針對個別病人。
Among those with late and very late ST, the prevalence of dual-antiplatelet therapy was 57% and 36%, respectively.
在發生晚期和極晚期ST的患者中，雙重抗血小板的應用比例分別占57%和36%。
In my opinion, it is not with triple therapy that we can solve this problem but with alternative antiplatelet agents.
我覺得，三重治療并不能解決問題，而應該選擇其他可選擇的抗血小板藥物。
Conclusion: Nearly 4 of 10 patients receiing warfarin management care were receiing warfarin and antiplatelet combination therapy.
結論：接受華法林治療的患者中有約4成進行著華法林和抗血小板聯合治療。
Antiplatelet Therapy Necessary at Least a Year with Drug-Eluting Stents
藥物洗脫支架至少需要抗血小板治療一年
